FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4289313908> ?p ?o ?g. }

• W4289313908 endingPage "107205" @default.
• W4289313908 startingPage "107205" @default.
• W4289313908 abstract "Secondary pharmacology studies are a time-efficient and cost-effective method for determining the safety profile of a potential new drug before it enters human trials. The results of these multi-target screens are commonly submitted with Investigational New Drug (IND) applications, but there currently is little guidance on how such information is presented and which targets are chosen for testing. In this study, we expand on our previous analysis of secondary pharmacology reports by manually curating and analyzing all secondary pharmacology results received by the FDA received as part of an IND submission. A total of 1120 INDs submitted by 480 sponsors between 1999 and October 2020 were included in this study. The overall results were largely consistent with previous internal and external studies, showing that the most tested target in our set was the histamine 1 receptor (tested 938 times), the most hit target was sodium channel site 2 (hit 141 times), and the target with the highest hit percentage was the vesicular monoamine transporter 2 (hit 42.2% of the time). Additionally, this study demonstrated that improvements in the secondary pharmacology submission process, such as changes in formatting and nomenclature, could enhance the utility of these assays for regulatory review, including assisting with identifying the safety liabilities of a drug candidate early in development. This updated data set will allow FDA-industry collaborative working groups to continue developing the best methods for regulatory submission of secondary pharmacology data and evaluate the need for a standard target panel." @default.
• W4289313908 created "2022-08-02" @default.
• W4289313908 creator A5023779153 @default.
• W4289313908 creator A5043119124 @default.
• W4289313908 creator A5048768725 @default.
• W4289313908 creator A5060886434 @default.
• W4289313908 creator A5061717169 @default.
• W4289313908 date "2022-09-01" @default.
• W4289313908 modified "2023-09-26" @default.
• W4289313908 title "Analysis of secondary pharmacology assays received by the US Food and Drug Administration" @default.
• W4289313908 cites W1534250556 @default.
• W4289313908 cites W1965258805 @default.
• W4289313908 cites W2011767927 @default.
• W4289313908 cites W2018453465 @default.
• W4289313908 cites W2019939591 @default.
• W4289313908 cites W2026589900 @default.
• W4289313908 cites W2032119990 @default.
• W4289313908 cites W2055305943 @default.
• W4289313908 cites W2064225780 @default.
• W4289313908 cites W2092844371 @default.
• W4289313908 cites W2117050502 @default.
• W4289313908 cites W2123477530 @default.
• W4289313908 cites W2133496177 @default.
• W4289313908 cites W2138354938 @default.
• W4289313908 cites W2148208755 @default.
• W4289313908 cites W2343227460 @default.
• W4289313908 cites W2412416040 @default.
• W4289313908 cites W2553315459 @default.
• W4289313908 cites W2588796969 @default.
• W4289313908 cites W2793907994 @default.
• W4289313908 cites W2802163240 @default.
• W4289313908 cites W2884015482 @default.
• W4289313908 cites W2887592114 @default.
• W4289313908 cites W2986944330 @default.
• W4289313908 cites W3033314946 @default.
• W4289313908 cites W3097245056 @default.
• W4289313908 cites W4237263683 @default.
• W4289313908 cites W4238102997 @default.
• W4289313908 doi "https://doi.org/10.1016/j.vascn.2022.107205" @default.
• W4289313908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35926773" @default.
• W4289313908 hasPublicationYear "2022" @default.
• W4289313908 type Work @default.
• W4289313908 citedByCount "2" @default.
• W4289313908 countsByYear W42893139082022 @default.
• W4289313908 countsByYear W42893139082023 @default.
• W4289313908 crossrefType "journal-article" @default.
• W4289313908 hasAuthorship W4289313908A5023779153 @default.
• W4289313908 hasAuthorship W4289313908A5043119124 @default.
• W4289313908 hasAuthorship W4289313908A5048768725 @default.
• W4289313908 hasAuthorship W4289313908A5060886434 @default.
• W4289313908 hasAuthorship W4289313908A5061717169 @default.
• W4289313908 hasBestOaLocation W42893139081 @default.
• W4289313908 hasConcept C2776190711 @default.
• W4289313908 hasConcept C2779446555 @default.
• W4289313908 hasConcept C2780035454 @default.
• W4289313908 hasConcept C3018890749 @default.
• W4289313908 hasConcept C63433958 @default.
• W4289313908 hasConcept C71924100 @default.
• W4289313908 hasConcept C98274493 @default.
• W4289313908 hasConceptScore W4289313908C2776190711 @default.
• W4289313908 hasConceptScore W4289313908C2779446555 @default.
• W4289313908 hasConceptScore W4289313908C2780035454 @default.
• W4289313908 hasConceptScore W4289313908C3018890749 @default.
• W4289313908 hasConceptScore W4289313908C63433958 @default.
• W4289313908 hasConceptScore W4289313908C71924100 @default.
• W4289313908 hasConceptScore W4289313908C98274493 @default.
• W4289313908 hasFunder F4320306084 @default.
• W4289313908 hasFunder F4320332163 @default.
• W4289313908 hasFunder F4320332382 @default.
• W4289313908 hasLocation W42893139081 @default.
• W4289313908 hasLocation W42893139082 @default.
• W4289313908 hasLocation W42893139083 @default.
• W4289313908 hasOpenAccess W4289313908 @default.
• W4289313908 hasPrimaryLocation W42893139081 @default.
• W4289313908 hasRelatedWork W1509385305 @default.
• W4289313908 hasRelatedWork W1517960625 @default.
• W4289313908 hasRelatedWork W1603416295 @default.
• W4289313908 hasRelatedWork W1965554264 @default.
• W4289313908 hasRelatedWork W2005299836 @default.
• W4289313908 hasRelatedWork W2076120318 @default.
• W4289313908 hasRelatedWork W2412649122 @default.
• W4289313908 hasRelatedWork W2417979035 @default.
• W4289313908 hasRelatedWork W2897979832 @default.
• W4289313908 hasRelatedWork W372931616 @default.
• W4289313908 hasVolume "117" @default.
• W4289313908 isParatext "false" @default.
• W4289313908 isRetracted "false" @default.
• W4289313908 workType "article" @default.